US 11,944,466 B2
Method and apparatus for monitoring virus variant risk during an epidemic and pandemic
Ophir Frieder, Chevy Chase, MD (US); Abdur Chowdhury, San Francisco, CA (US); and Eric Jensen, Brooklyn, NY (US)
Assigned to AURA HOME, INC., San Francisco, CA (US)
Filed by AURA HOME, INC., San Francisco, CA (US)
Filed on Jul. 18, 2022, as Appl. No. 17/866,987.
Application 17/866,987 is a continuation in part of application No. 17/317,177, filed on May 11, 2021, granted, now 11,510,633.
Application 17/317,177 is a continuation of application No. 17/130,639, filed on Dec. 22, 2020, granted, now 11,013,472.
Application 17/130,639 is a continuation in part of application No. 17/038,064, filed on Sep. 30, 2020, granted, now 10,945,680.
Application 17/038,064 is a continuation of application No. 16/432,373, filed on Jun. 5, 2019, granted, now 10,813,599.
Application 16/432,373 is a continuation of application No. 16/046,590, filed on Jul. 26, 2018, granted, now 10,314,550.
Application 16/046,590 is a continuation of application No. 15/291,819, filed on Oct. 12, 2016, granted, now 10,039,504.
Application 15/291,819 is a continuation of application No. 14/848,881, filed on Sep. 9, 2015, granted, now 9,498,163.
Application 14/848,881 is a continuation in part of application No. 14/751,399, filed on Jun. 26, 2015, granted, now 9,439,038.
Application 14/751,399 is a continuation in part of application No. 14/455,297, filed on Aug. 8, 2014, granted, now 9,420,015.
Application 14/455,297 is a continuation in part of application No. 14/455,279, filed on Aug. 8, 2014, granted, now 9,386,052.
Application 14/455,279 is a continuation in part of application No. 14/270,534, filed on May 6, 2014, granted, now 9,288,616.
Application 14/455,297 is a continuation in part of application No. 14/051,089, filed on Oct. 10, 2013, granted, now 9,338,759.
Application 14/051,089 is a continuation in part of application No. 14/051,071, filed on Oct. 10, 2013, granted, now 9,225,789.
Application 14/455,279 is a continuation in part of application No. 14/051,089.
Application 14/051,089 is a continuation in part of application No. 14/051,071.
Application 14/270,534 is a continuation in part of application No. 14/051,089.
Application 14/051,089 is a continuation in part of application No. 14/051,071.
Prior Publication US 2022/0361826 A1, Nov. 17, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61B 5/00 (2006.01); A61B 5/11 (2006.01); G06F 16/9535 (2019.01); G06F 21/55 (2013.01); G16H 40/63 (2018.01); G16Z 99/00 (2019.01); H04L 51/222 (2022.01); H04L 51/52 (2022.01); H04L 51/58 (2022.01); H04L 67/50 (2022.01); H04W 4/02 (2018.01); H04W 4/029 (2018.01); H04W 4/12 (2009.01); H04W 4/21 (2018.01); H04W 4/33 (2018.01); H04W 52/02 (2009.01); H04L 51/08 (2022.01); H04M 1/72454 (2021.01); H04W 64/00 (2009.01)
CPC A61B 5/746 (2013.01) [A61B 5/1112 (2013.01); A61B 5/1118 (2013.01); A61B 5/1123 (2013.01); A61B 5/4866 (2013.01); A61B 5/6898 (2013.01); A61B 5/72 (2013.01); A61B 5/7246 (2013.01); A61B 5/7267 (2013.01); A61B 5/7282 (2013.01); A61B 5/742 (2013.01); A61B 5/7455 (2013.01); A61B 5/7465 (2013.01); G06F 16/9535 (2019.01); G06F 21/552 (2013.01); G16H 40/63 (2018.01); G16Z 99/00 (2019.02); H04L 51/222 (2022.05); H04L 51/52 (2022.05); H04L 51/58 (2022.05); H04L 67/535 (2022.05); H04W 4/023 (2013.01); H04W 4/029 (2018.02); H04W 4/12 (2013.01); H04W 4/21 (2018.02); H04W 4/33 (2018.02); H04W 52/0229 (2013.01); H04W 52/0254 (2013.01); G06F 2221/2111 (2013.01); H04L 51/08 (2013.01); H04M 1/72454 (2021.01); H04W 64/006 (2013.01); Y02D 30/70 (2020.08)] 19 Claims
OG exemplary drawing
 
1. A method of determining infection risks for individuals during an epidemic or pandemic, the method executed by a computer system and comprising:
automatically determining positional destinations of a user using a first mobile electronic device of the user;
automatically determining context information about each of the positional destinations without input by the user;
automatically determining an infectious agent variant prevalence for the each of the positional destinations;
determining a first risk metric for the infectious agent prevalent at the each of the positional destinations;
determining a second risk metric for each of locations and/or activities for the user, to provide a plurality of risk metrics during the predetermined timeframe;
determining a corresponding user participation time for the each of the locations and/or activities;
scaling the second risk metric for the each of the locations and/or activities according to the corresponding user participation time;
assigning a user risk assessment to the user according to the variant prevalence at the each of the positional destinations by computing the user risk assessment from the first and second risk metrics; and
providing the user risk assessment to the user via the first mobile electronic device or a community member via a community member electronic device.